Collectively, we reveal a previously unappreciated role of PirB/LILRB2 in NASH pathogenesis and identified ANGPTL8-PirB-NF-κB signaling as a potential target for the management of NASH in the future. Here, ANGPTL8 is linked to metabolic dysfunction-associated steatohepatitis.